Sofinnova Investments

Previously, Dupont was global head of research & development and executive vice president at Atara Biotherapeutics.

Prior to joining Sofinnova, he was chief medical officer at Catamaran Bio.

Sofinnova Ventures is seeking to raise $600 million for its eleventh fund, according to an SEC filing.

Sofinnova Investments has promoted Dr. Maha Katabi to general partner and Dr. Sarah Bhagat to partner.

CinCor Pharma, a biopharmaceutical company, has secured $50 million in Series A funding. Sofinnova Investments led the round.

Silicon Valley biotechnology investment firm Sofinnova Investments has hired Maha Katabi as a partner. Katabi, who has worked as a Canadian venture capital and public equities professional for more than 18 years, joined from Oxalis Capital, an innovative therapeutics investor she founded in 2018. Previously, she was a partner at Sectoral Asset Management, a vice president at Ventures West Management and an associate at T2C2 Capital. With Katabi’s hire, Sofinnova said it will open an office in Montréal, enabling the firm to work more closely with companies based in the Eastern United States, Europe and Canada.

Silicon Valley biotechnology investment firm Sofinnova Investments has hired Maha Katabi as a partner. Katabi, who has worked as a Canadian venture capital and public equities professional for more than 18 years, joined from Oxalis Capital, an innovative therapeutics investor she founded in 2018. Previously, she was a partner at Sectoral Asset Management, a vice president at Ventures West Management, and an associate at T2C2 Capital. With Katabi's hire, Sofinnova said it will open an office in Montréal, enabling the firm to work more closely with companies based in the Eastern United States, Europe and Canada.

Boston-based Inozyme Pharma Inc, a biotechnology company, has raised $67 million in Series A2 financing. Pivotal bioVenture Partners and Sofinnova Investments led the round.

The UK-based fund of funds leverages the data from its nearly 40-year history to focus on a smaller number of managers it believes will consistently outperform the venture market.

Private equity's biggest hitters take aim at the $160 trillion retail market, according to panellists at IPEM Paris. Plus: PE and VC deal values hit a four-year low; and Australian private investments are outperforming publicly traded instruments. Here's today's brief, for our valued subscribers only.

Apollo has announced it will buy a minority stake in Paris-based life sciences VC firm Sofinnova Partners, following Carlyle's purchase of Abingworth and EQT's acquisition of LSP.

CinCor Pharma, a developer of treatment for hypertension and other cardio-renal diseases, has priced its IPO of 11 million shares at a price range between $15 and $17 per share.

Omega Funds has closed its seventh fund at $650 million, beating its $500 million target.

South San Francisco-based Vera Therapeutics, a biotech company, has raised $47.85 million for its IPO after pricing its 4.35 million shares at $11 per share.

London-based Gyroscope Therapeutics, a gene therapy company focused on treating eye diseases, has postponed its IPO plans, citing market conditions as the reason.

Gyroscope Therapeutics, a gene therapy company, has filed for an IPO.